After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to slim down by divesting its hospital drugs unit, Reuters reports, citing people familiar with the matter. The hospital unit was itself the result of a major acquisition, formed after Pfizer shelled out $17 billion to purchase Hospira in 2015. But now, Pfizer has tapped Goldman Sachs to gauge interest from potential buyers such as private equity shops and other drugmakers, the sources said, according to Reuters.
Read the full article: Pfizer Explores Sale of Hospital Drugs Unit amid Activist Investor’s Call for Accountability //
Source: https://www.fiercepharma.com/pharma/pfizer-explores-sale-hospital-drugs-unit-amid-activist-investors-call-accountability-reuters